{"url_path":"/sec/fulc/8-k/2026-06-25/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-282873-index.html","accession_number":"0001193125-26-282873","cik":"0001680581","ticker":"FULC","issuer_name":"Fulcrum Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-282873-index.html","primary_entity_key":"0001680581","primary_entity_name":"Fulcrum Therapeutics, Inc."},"word_count":287,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Fulcrum Therapeutics, Inc., or Fulcrum, held on June 24, 2026, or the Annual Meeting.\n\n \n\n \na)\n\nFulcrum’s stockholders elected Sonja Banks, Alan Ezekowitz, and Colin Hill as class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2029 and each until her or his respective successor has been duly elected and qualified or until her or his earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the three Class I directors are as follows:\n\n \n\nName\n\n  \nVotes\nFor\n \n  \nVotes\nWithheld\n \n  \nBroker\nNon-Votes\n \n\nSonja Banks\n\n  \n \n43,187,717\n \n  \n \n10,601,385\n \n  \n \n5,062,117\n \n\nAlan Ezekowitz\n\n  \n \n52,317,282\n \n  \n \n1,471,820\n \n  \n \n5,062,117\n \n\nColin Hill\n\n  \n \n52,363,595\n \n  \n \n1,425,507\n \n  \n \n5,062,117\n \n\n \n\n \nb)\n\nFulcrum’s stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum’s named executive officers. The results of the stockholders’ vote with respect to such vote are as follows:\n\n \n\nVotes\n\nFor\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker\nNon-Votes\n\n50,735,617\n \n3,026,397\n \n27,088\n \n5,062,117\n\n \n\n \nd)\n\nFulcrum’s stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification are as follows:\n\n \n\nVotes\n\nFor\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker\nNon-Votes\n\n58,793,645\n \n36,178\n \n21,396\n \n0\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nFULCRUM THERAPEUTICS, INC.\n\nDate: June 25, 2026\n \n\n \nBy:\n \n\n/s/ Curtis Oltmans\n\n \n\n \nName:\n \nCurtis Oltmans\n\n \n\n \nTitle:\n \nChief Legal Officer and Head of External Affairs"}